Morgan Stanley
ADXN

Morgan Stanley’s Addex Therapeutics ADXN Stock Holding History

Morgan Stanley’s Portfolio ADXN Stock Details ADXN Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2026
Q1 		$1.89K Buy
301
+1
+0.3% +$7 ﹤0.01% 7341
2025
Q4 		$2.32K Buy
+300
New +$2.57K ﹤0.01% 7217
2025
Q3 		– Sell
-100
Closed -$941 – 8162
2025
Q2 		$941 Hold
100
– – ﹤0.01% 7340
2025
Q1 		$734 Sell
100
-1,800
-95% -$13.9K ﹤0.01% 7324
2024
Q4 		$13.3K Buy
1,900
+1,547
+438% +$14.1K ﹤0.01% 6703
2024
Q3 		$3.45K Sell
353
-1,147
-76% -$10.2K ﹤0.01% 7007
2024
Q2 		$12.3K Buy
+1,500
New +$18.5K ﹤0.01% 6609

Other funds holding ADXN

GI
GAMMA Investing Foster City, California $2.69B AUM 42.78% 1-Year Est. Return
RhumbLine Advisers
RhumbLine Advisers Boston, Massachusetts $117B AUM 29.66% 1-Year Est. Return
SS
SBI Securities Tokyo, Japan $4.4B AUM 74.26% 1-Year Est. Return

Morgan Stanley's ADXN Position: Q1 2026 in Review

Morgan Stanley increased its Addex Therapeutics (ADXN) stake by 0.33% in Q1 2026, buying an estimated $7 and bringing the position to 301 shares worth $1.89K. The position accounts for ﹤0.01% of the portfolio, ranked #7341.

Morgan Stanley first reported a position in ADXN in Q2 2024 and has held it in 7 quarters since. The position peaked at $13.3K in Q4 2024. 4 funds tracked by Wall St. Rank hold ADXN as of Q1 2026.

  • Morgan Stanley held 301 shares of Addex Therapeutics worth $1.89K as of Q1 2026.
  • Morgan Stanley bought 1 Addex Therapeutics share in Q1 2026, an estimated $7.
  • Addex Therapeutics made up ﹤0.01% of Morgan Stanley's portfolio in Q1 2026, its #7341 holding.
  • Morgan Stanley first reported a position in Addex Therapeutics in Q2 2024 and has held it in 7 quarters since.
  • Morgan Stanley's Addex Therapeutics position peaked at $13.3K in Q4 2024.
  • 4 funds tracked by Wall St. Rank held Addex Therapeutics as of Q1 2026.

Based on Morgan Stanley's 13F filing for Q1 2026, filed 15 May 2026.